# A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07208773/  
OnCo record `nct07208773` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of YL201, Ivonescimab in non-small-cell lung cancer and small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07208773 by MediLink Therapeutics (Suzhou) Co., Ltd., with 260 participants planned, started 2025-10-29 and due to reach its primary completion in 2027-01. Interventions recorded: YL201, Ivonescimab. Conditions listed: Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07208773
- Phase: 1/2
- Setting: A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of YL201 in Combination With Ivonescimab in Patients With Advanced Solid Tumors
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT07208773: https://clinicaltrials.gov/study/NCT07208773

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [YL201](https://onco.cc/drugs/yl201/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/)

---
JSON: https://onco.cc/api/v1/entities/nct07208773.json